You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – A number of factors influence the poor response that osteosarcomas have to immune checkpoint inhibitor therapy, a new study profiling the tumors has found.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.